Samantha Truex, Upstream Bio CEO

Up­stream Bio match­es first fund­ing round with an­oth­er $200M to get asth­ma drug to PhI­II

Up­stream Bio has raised an­oth­er $200 mil­lion to go through Phase II stud­ies and pre­pare for late-stage tri­als of an ex-Astel­las mon­o­clon­al an­ti­body in an­tic­i­pa­tion of com­pe­ti­tion with As­traZeneca and Am­gen’s asth­ma drug Tezspire.

The raise, dis­closed Thurs­day morn­ing, mir­rors its first fund­ing round from 2021 that bankrolled the Waltham, MA-based start­up’s on­go­ing Phase Ib in asth­ma. It plans to use the new round to sup­port mid-stage stud­ies in both asth­ma and chron­ic rhi­nos­i­nusi­tis with nasal polyps. Both of those stud­ies will kick off in the first quar­ter of 2024, CEO Saman­tha Truex told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.